Fourth, while our results demonstrated therapeutic benefits of ROCK2 inhibition during both acute and chronic (two months) phases of epilepsy, longer‐term follow‐up studies are needed to evaluate the durability of these effects and monitor potential adverse outcomes associated with extended treatment. Here, ROCK2 is linked to epilepsy.